NCT02183038

Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis

Double-blind Study to Compare Efficacy and Safety of Meloxicam 7.5 mg and 15 mg vs. Naproxen Sodium 1100 mg in the Symptomatic Treatment of Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis Over a Period of 5 Days

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 390 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study to assess the efficacy and tolerability of Meloxicam once daily dose of 7.5 mg and 15 mg compared with 1100 mg of naproxen sodium in the symptomatic treatment of acute non bacterial pharyngitis or pharyngo-tonsillitis, over a period of 5 days.

Conditions

• Pharyngitis

Interventions

Type	Name	Description
DRUG	Meloxicam low
DRUG	Meloxicam high
DRUG	Naproxen sodium
DRUG	Meloxicam placebo low
DRUG	Meloxicam placebo high
DRUG	Naproxen sodium placebo

Timeline

• Start date: 1998-07-01
• Primary completion: 1999-02-01
• First posted: 2014-07-08
• Last updated: 2014-07-08